Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 228

1.

Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.

Csajka C, Marzolini C, Fattinger K, Décosterd LA, Fellay J, Telenti A, Biollaz J, Buclin T.

Clin Pharmacol Ther. 2003 Jan;73(1):20-30.

PMID:
12545140
[PubMed - indexed for MEDLINE]
2.

Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals.

Kappelhoff BS, Huitema AD, Yalvaç Z, Prins JM, Mulder JW, Meenhorst PL, Beijnen JH.

Clin Pharmacokinet. 2005;44(8):849-61.

PMID:
16029069
[PubMed - indexed for MEDLINE]
3.

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.

Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T.

AIDS. 2001 Jan 5;15(1):71-5.

PMID:
11192870
[PubMed - indexed for MEDLINE]
4.

Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study.

Kappelhoff BS, van Leth F, MacGregor TR, Lange J, Beijnen JH, Huitema AD; 2NN Study Group.

Antivir Ther. 2005;10(1):145-55.

PMID:
15751772
[PubMed - indexed for MEDLINE]
5.

Efavirenz and nevirapine in HIV-1 infection : is there a role for clinical pharmacokinetic monitoring?

Dahri K, Ensom MH.

Clin Pharmacokinet. 2007;46(2):109-32. Review.

PMID:
17253884
[PubMed - indexed for MEDLINE]
6.

Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus.

Csajka C, Marzolini C, Fattinger K, Décosterd LA, Telenti A, Biollaz J, Buclin T.

Antimicrob Agents Chemother. 2004 Sep;48(9):3226-32.

PMID:
15328077
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Intra-individual variability in efavirenz plasma concentrations supports therapeutic drug monitoring based on quarterly sampling in the first year of therapy.

Pereira SA, Branco T, Caixas U, Côrte-Real RM, Germano I, Lampreia F, Monteiro EC.

Ther Drug Monit. 2008 Feb;30(1):60-6. doi: 10.1097/FTD.0b013e318160ce76.

PMID:
18223464
[PubMed - indexed for MEDLINE]
8.

Population pharmacokinetic meta-analysis with efavirenz.

Barrett JS, Joshi AS, Chai M, Ludden TM, Fiske WD, Pieniaszek HJ Jr.

Int J Clin Pharmacol Ther. 2002 Nov;40(11):507-19.

PMID:
12698988
[PubMed - indexed for MEDLINE]
9.

The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons.

Veldkamp AI, Harris M, Montaner JS, Moyle G, Gazzard B, Youle M, Johnson M, Kwakkelstein MO, Carlier H, van Leeuwen R, Beijnen JH, Lange JM, Reiss P, Hoetelmans RM.

J Infect Dis. 2001 Jul 1;184(1):37-42. Epub 2001 May 30.

PMID:
11398107
[PubMed - indexed for MEDLINE]
Free Article
10.

Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection.

Colombo S, Buclin T, Cavassini M, Décosterd LA, Telenti A, Biollaz J, Csajka C.

Antimicrob Agents Chemother. 2006 Nov;50(11):3801-8. Epub 2006 Aug 28.

PMID:
16940065
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects.

DiCenzo R, Forrest A, Squires KE, Hammer SM, Fischl MA, Wu H, Cha R, Morse GD; Adult AIDS Clinical Trials Group Protocol 368/886 Study Team.

Antimicrob Agents Chemother. 2003 Jun;47(6):1929-35.

PMID:
12760869
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring.

Gutiérrez F, Navarro A, Padilla S, Antón R, Masiá M, Borrás J, Martín-Hidalgo A.

Clin Infect Dis. 2005 Dec 1;41(11):1648-53. Epub 2005 Oct 19.

PMID:
16267739
[PubMed - indexed for MEDLINE]
Free Article
13.

Intracellular and plasma efavirenz concentrations in HIV-infected patients switching from successful protease inhibitor-based highly active antiretroviral therapy (HAART) to efavirenz-based HAART (SUSTIPHAR Study).

Djabarouti S, Breilh D, Pellegrin I, Lavit M, Camou F, Caubet O, Fleury H, Saux MC, Pellegrin JL.

J Antimicrob Chemother. 2006 Nov;58(5):1090-3. Epub 2006 Aug 18.

PMID:
16921181
[PubMed - indexed for MEDLINE]
Free Article
14.

Are adverse events of nevirapine and efavirenz related to plasma concentrations?

Kappelhoff BS, van Leth F, Robinson PA, MacGregor TR, Baraldi E, Montella F, Uip DE, Thompson MA, Russell DB, Lange JM, Beijnen JH, Huitema AD; 2NN Study Group.

Antivir Ther. 2005;10(4):489-98.

PMID:
16038474
[PubMed - indexed for MEDLINE]
15.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
[PubMed - indexed for MEDLINE]
16.

A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.

Manosuthi W, Sungkanuparph S, Tantanathip P, Lueangniyomkul A, Mankatitham W, Prasithsirskul W, Burapatarawong S, Thongyen S, Likanonsakul S, Thawornwa U, Prommool V, Ruxrungtham K; N2R Study Team.

Clin Infect Dis. 2009 Jun 15;48(12):1752-9. doi: 10.1086/599114.

PMID:
19438397
[PubMed - indexed for MEDLINE]
Free Article
17.

Clinical pharmacokinetics of nelfinavir combined with efavirenz and stavudine during rescue treatment of heavily pretreated HIV-infected patients.

Regazzi MB, Villani P, Maserati R, Seminari E, Pan A, LoCaputo F, Gambarana E, Fiocchi C.

J Antimicrob Chemother. 2000 Mar;45(3):343-7.

PMID:
10702554
[PubMed - indexed for MEDLINE]
Free Article
18.

Efavirenz plasma levels for the prediction of treatment failure in heavily pretreated HIV-1 infected patients.

Langmann P, Weissbrich B, Desch S, Väth T, Schirmer D, Zilly M, Klinker H.

Eur J Med Res. 2002 Jul 24;7(7):309-14.

PMID:
12176680
[PubMed - indexed for MEDLINE]
19.

Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.

Semvua HH, Mtabho CM, Fillekes Q, van den Boogaard J, Kisonga RM, Mleoh L, Ndaro A, Kisanga ER, van der Ven A, Aarnoutse RE, Kibiki GS, Boeree MJ, Burger DM.

Antivir Ther. 2013;18(1):105-13. doi: 10.3851/IMP2413. Epub 2012 Oct 5.

PMID:
23043067
[PubMed - indexed for MEDLINE]
20.

Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors.

Smith PF, Robbins GK, Shafer RW, Wu H, Yu S, Hirsch MS, Merigan TC, Park JG, Forrest A, Fischl MA, Morse GD; ACTG 384-5006 Team.

Antimicrob Agents Chemother. 2005 Aug;49(8):3558-61.

PMID:
16048984
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk